The U.S. FDA approved Technivie for use in combination with ribavirin for the treatment of hepatitis C virus (HCV) genotype 4 infections in patients without scarring and cirrhosis. Technivie is developed and marked by AbbVie, a research-based biopharmaceutical company headquartered in North Chicago, IL. It is composed of three antiviral components, ombitasvir, paritaprevir and ritonavir, each of which has a distinct mechanism of action that work together to attack HCV at different stages of the disease lifecycle to inhibit the virus from reproducing. The three antiviral drugs in Technivie are also present in Viekira Pak, another product of AbbVie (ombitasvir/paritaprevir/ritonavir and dasabuvir) approved by the FDA at the end of last year for treatment of adults with HCV genotype 1 without cirrhosis. According to the FDA, Technivie in combination with ribavirin is “the first drug that has demonstrated safety and efficacy to treat genotype 4 HCV infections without the need for co-administration of interferon”, another drug approved for HCV infection. The HCV is a bloodborne virus transmitted most commonly through unsafe injection practices, inadequate sterilization of medical equipment and the transfusion of unscreened blood and blood products. It is estimated that 130-150 million people globally have chronic hepatitis C, according to the World Health Organization.